Can a new biosimilar match Neulasta's power to rebuild white blood cells?

This trial is testing whether an experimental drug called NKF-PEG works in the same way as the approved medicine Neulasta. Both are designed to help the body produce more white blood cells, which are important for fighting infection. Healthy adult male volunteers will receive a single injection of each drug at different times, and researchers will compare how the drugs are absorbed and how strongly they stimulate white blood cell production. The goal is to see if NKF-PEG could be a similar, potentially more affordable alternative to Neulasta.